Artificial Intelligence In Drug Repurposing Market Report 2026

Artificial Intelligence In Drug Repurposing Market Overview

• Artificial Intelligence In Drug Repurposing market size has reached to $1.05 billion in 2025 • Expected to grow to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 20.1% • Growth Driver: Rising Demand For Precision Medicine Fueling The Growth Of The Market Due To Increasing Preference For Personalized And Targeted Therapies • Market Trend: Accelerating Treatment Discovery Through Technology Integration • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence In Drug Repurposing Market?

Artificial intelligence in drug repurposing refers to the application of artificial intelligence techniques to identify new medical uses for existing drugs. It utilizes advanced data analytics, machine learning, and predictive modelling to analyse biological, chemical, and clinical data for potential therapeutic matches. This approach accelerates drug discovery, reduces research costs, and enhances the efficiency of pharmaceutical development. The main components of artificial intelligence in drug repurposing include software and platforms and services. Software and platforms include digital tools and environments that enable the development, deployment, and use of applications and services. It uses various technologies such as machine learning or deep learning, natural language processing (NLP), knowledge graphs and network-based artificial intelligence, generative artificial intelligence and large language models (LLMs), and computer vision, and different deployment modes include cloud-based and on-premises. Various therapeutic areas include oncology, neurology, cardiovascular diseases, infectious diseases, immunology, metabolic disorders, and rare diseases and cater to several end-users, including pharmaceutical and biotechnology companies, contract research organizations (CROs), academic and research institutes, healthcare providers, and others.

What Is The Artificial Intelligence In Drug Repurposing Market Growth Forecast?

The artificial intelligence in drug repurposing market size is expected to see exponential growth in the next few years. It will grow to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to growth of AI-assisted clinical decision support, increasing use of generative AI for molecule insights, need for faster repurposing during health crises, expansion of real-world evidence analytics, rising investments in precision medicine pipelines. Major trends in the forecast period include AI-driven drug-target matching from multi-omics data, repurposing pipelines using knowledge graph discovery, virtual screening and trial simulation acceleration, federated learning for cross-institution research, explainable AI for clinical repurposing decisions.

Global Artificial Intelligence In Drug Repurposing Market Segmentation

1) By Component: Software And Platforms, Services 2) By Technology: Machine Learning Or Deep Learning, Natural Language Processing (NLP), Knowledge Graphs And Network-Based Artificial Intelligence, Generative Artificial Intelligence And Large Language Models (LLMs), Computer Vision 3) By Deployment: Cloud-Based, On-Premises 4) By Therapeutic Area: Oncology, Neurology, Cardiovascular Diseases, Infectious Diseases, Immunology, Metabolic Disorders, Rare Diseases 5) By End-User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Healthcare Providers, Other End-Users Subsegments: 1) By Software And Platforms: Predictive Analytics Tools, Machine Learning Frameworks, Data Integration Systems, Drug Discovery Platforms, Clinical Trial Simulation Tools 2) By Services: Consulting Services, Data Management Services, Model Training And Optimization Services, Implementation And Integration Services, Support And Maintenance Services

What Is The Driver Of The Artificial Intelligence In Drug Repurposing Market?

The growing demand for precision medicine is expected to propel the growth of the artificial intelligence in drug repurposing market going forward. Precision medicine is a healthcare approach that customizes disease prevention and treatment based on an individual’s specific genes, behaviors, and environment. Rising demand for personalized treatments is driving the growth of precision medicine, as patients and healthcare providers increasingly seek therapies tailored to individual genetic and lifestyle profiles for improved effectiveness and reduced side effects. AI-driven drug repurposing enhances precision medicine by discovering existing drugs that align with an individual’s genetic or molecular characteristics, enabling more accurate and personalized treatment solutions. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA granted approval for 16 personalized therapies targeting rare diseases in 2023, a notable rise compared to the six approvals issued in 2022. Therefore, the growing demand for precision medicine is driving the growth of the artificial intelligence in drug repurposing industry.

Key Players In The Global Artificial Intelligence In Drug Repurposing Market

Major companies operating in the artificial intelligence in drug repurposing market are IBM Corporation, Evogene Ltd., Ginkgo Bioworks Holdings Inc., BioAge Labs Inc., Insilico Medicine Inc., BostonGene Corporation, ISOMORPHIC LABS, Recursion Pharmaceuticals Inc., Deep Genomics Inc., Healx Ltd., Owkin Inc., BullFrog AI Holdings Inc., Aicura Medical GmbH, Kantify, Ignota Labs Ltd., OrphAI Therapeutics, Nabla Bio, Atomwise Inc., BioXcel Therapeutics Inc., Graph AI.

Global Artificial Intelligence In Drug Repurposing Market Trends and Insights

Major companies operating in the artificial intelligence in drug repurposing market are focusing on the integration of advanced technologies in drug repositioning, such as computational drug repositioning systems, which systematically identify new therapeutic indications for existing drugs using data-driven analysis of literature and biological information. A computational drug repositioning system refers to a technology-driven platform that uses artificial intelligence, machine learning, and data mining to systematically analyze existing drugs, compounds, and biological data. For instance, in November 2023, Tempus, a US-based provider of AI-based precision medicine solutions, announced a multi-year strategic collaboration with Recursion, a US-based clinical stage biotechnology company, valued at up to $160 million over five years. The collaboration provides Recursion with access to Tempus’ extensive library of de-identified, multimodal oncology data to support biomarker-driven therapeutic development. By leveraging Tempus’ large-scale patient datasets alongside Recursion’s AI-enabled discovery capabilities, the partnership strengthens oncology drug repurposing initiatives, demonstrating how advanced computational platforms combined with real-world clinical data can accelerate the discovery of new treatment opportunities.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence In Drug Repurposing Market?

In January 2024, Cosmos Health Inc., a US-based diversified healthcare company, acquired Cloudscreen for an undisclosed amount. Through this acquisition, Cosmos Health aims to enhance drug repurposing capabilities and accelerate the identification of new therapeutic applications for existing drugs. Cloudscreen is a US-based company specializing in AI-powered drug repurposing solutions.

Regional Insights

North America was the largest region in the artificial intelligence in drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence In Drug Repurposing Market?

The artificial intelligence in drug repurposing market includes revenues earned by entities by providing services such as predictive modelling, target identification, drug-disease interaction analysis, virtual screening, and clinical data mining. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence In Drug Repurposing Market Report 2026?

The artificial intelligence in drug repurposing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in drug repurposing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.